AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14727476 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac patch
Number of subjects: 0
Study 14727476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11590486 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 23
Study 11590486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9297763 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified urodynamics test including epithelial leak test, filling cystometrogram, bladder emptying, instilling lidocaine intravesically, and repeat cystometrogram after bladder emptying.
Number of subjects: 0
Study 9297763 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified urodynamics test
Number of subjects: 0
Study 8877234 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms b.i.d. (aerosol or aqua)
Number of subjects: 91
Study 8877234 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aerosol or aqua)
Number of subjects: 91
Study 3598997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg twice daily for 4 weeks
Number of subjects: 16
Study 3598997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine treatment
Number of subjects: 16
Study 3598997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg sublingually
Number of subjects: 16
Study 3598997 — intervention group
Group type: EXPERIMENTAL
Intervention: Longterm treatment (16-20 weeks) with Nifedipine
Number of subjects: 16
Study 29690916 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined protocol for the treatment of SAM and MAM
Number of subjects: 3600
Study 29690916 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (national treatment protocol)
Number of subjects: 3600
Study 27117555 — intervention group
Group type: EXPERIMENTAL
Intervention: CATTS service delivery model (telepsychiatry + caregiver behavior management training)
Number of subjects: 223
Study 27117555 — intervention group
Group type: COMPARATOR
Intervention: Augmented Primary Care (APC) service model (primary care management + single telepsychiatry consultation)
Number of subjects: 223
Study 24213958 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal stimulation of the motor cortex, 10 days, 20 minutes, 2 mA, twice a day)
Number of subjects: 16
Study 24213958 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 16
Study 22469279 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 307
Study 19174493 — intervention group
Group type: EXPERIMENTAL
Intervention: Capromorelin (10 mg three times/week, 3 mg twice a day, 10 mg each night, and 10 mg twice a day)
Number of subjects: 395
Study 19174493 — intervention group
Group type: EXPERIMENTAL
Intervention: Capromorelin (various doses)
Number of subjects: 395
Study 17900457 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of intradialytic progressive resistance training (PRT) plus usual care
Number of subjects: 49
Study 17900457 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of usual care followed by 12 weeks of PRT plus usual care
Number of subjects: 49
Study 16300168 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg with Lovastatin 40 mg
Number of subjects: 15
Study 16300168 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg with Atenolol 100 mg
Number of subjects: 15
Study 16300168 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg with Celecoxib 200 mg
Number of subjects: 15
Study 16300168 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg with Cimetidine 800 mg
Number of subjects: 15
Study 16300168 — intervention group
Group type: COMPARATOR
Intervention: Aliskiren alone
Number of subjects: 15
Study 12492271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle cryotherapy (30 minutes with a crushed ice bag)
Number of subjects: 30
Study 12492271 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as the remaining 15 subjects without cryotherapy)
Number of subjects: 30
Study 12492271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle cryotherapy
Number of subjects: 30
Study 9817052 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 120
Study 9817052 — intervention group
Group type: COMPARATOR
Intervention: Iotrolan
Number of subjects: 120
Study 7714229 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral SDZ ENS-163 with intravenous saline
Number of subjects: 18
Study 7714229 — intervention group
Group type: COMPARATOR
Intervention: Placebo with intravenous scopolamine
Number of subjects: 18
Study 7714229 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral SDZ ENS-163 with intravenous scopolamine
Number of subjects: 18
Study 7714229 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo with intravenous saline
Number of subjects: 18
Study 1776216 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 22
Study 1776216 — intervention group
Group type: COMPARATOR
Intervention: Enprofylline
Number of subjects: 22
Study 719418 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical teams
Number of subjects: 276
Study 719418 — intervention group
Group type: COMPARATOR
Intervention: Psychiatrists
Number of subjects: 276
Study 30476258 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-community treatment program (Bull City Fit)
Number of subjects: 97
Study 30476258 — intervention group
Group type: COMPARATOR
Intervention: Clinic-only treatment program
Number of subjects: 97
Study 30476258 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment programs
Number of subjects: 97
Study 30399019 — intervention group
Group type: EXPERIMENTAL
Intervention: Early peritoneal dialysis
Number of subjects: 239
Study 30399019 — intervention group
Group type: COMPARATOR
Intervention: Late peritoneal dialysis
Number of subjects: 239
Study 26084554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine plus 0.1% hyaluronic acid mouthwash (CHX⊗HYL group)
Number of subjects: 40
Study 26084554 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash (CHX group)
Number of subjects: 40
Study 26088793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg (DEX)
Number of subjects: 243
Study 26088793 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 243
Study 23496872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus fluid resuscitation
Number of subjects: 3141
Study 21576708 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐directional elastic‐resistance exercise training 2 times/wk for 4 wk
Number of subjects: 40
Study 21576708 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 19270510 — intervention group
Group type: EXPERIMENTAL
Intervention: Four field technique (Arm A)
Number of subjects: 83
Study 19270510 — intervention group
Group type: COMPARATOR
Intervention: Two field technique (Arm B)
Number of subjects: 83
Study 19270510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 83
Study 17091056 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior emergency physician placed with the triage nurse during peak periods (experimental group)
Number of subjects: 20
Study 17091056 — intervention group
Group type: COMPARATOR
Intervention: Traditional workflow without senior emergency physician (control group)
Number of subjects: 20
Study 15920337 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 198
Study 15920337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 12953725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1 microg/ml in normal saline (Group S)
Number of subjects: 34
Study 12953725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1 microg/ml with bupivacaine 0.125% (Group SB)
Number of subjects: 34
Study 10394092 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogues for 24 weeks followed by several therapeutic schemes
Number of subjects: 40
Study 10394092 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study 7677723 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rehearsal treatment
Number of subjects: 58
Study 7677723 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 58
Study 2288408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (0.5 mg/kg)
Number of subjects: 60
Study 2288408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7015174 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of kanamycin 500 mg plus clindamycin 600 mg intramuscularly
Number of subjects: 49
Study 7015174 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 49
Study 30992395 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB implant
Number of subjects: 150
Study 28318766 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 300
Study 28318766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 300
Study 28318766 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth (after first day of life)
Number of subjects: 300
Study 25500220 — intervention group
Group type: EXPERIMENTAL
Intervention: S4HM intervention (6-month multi-component intervention including an interactive seminar, eHealth messaging, behavioral contract, parental newsletters)
Number of subjects: 322
Study 23279732 — intervention group
Group type: EXPERIMENTAL
Intervention: narafilcon A (1 DAY ACUVUE(®) TruEye™) lenses
Number of subjects: 74
Study 23279732 — intervention group
Group type: COMPARATOR
Intervention: no contact lenses
Number of subjects: 74
Study 21226941 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily group psychoeducation (MFG) with concurrent cognitive remediation
Number of subjects: 40
Study 21226941 — intervention group
Group type: COMPARATOR
Intervention: Multifamily group psychoeducation (MFG) alone
Number of subjects: 40
Study 18853097 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE‐MRI at day‐1 after reperfused STEMI
Number of subjects: 0
Study 18853097 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE‐MRI at day‐7 after reperfused STEMI
Number of subjects: 0
Study 18853097 — intervention group
Group type: COMPARATOR
Intervention: DCE‐MRI at day‐1 and day‐7
Number of subjects: 0
Study 17135598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 553
Study 17135598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 17135598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion with HL genotype at COMT locus
Number of subjects: 553
Study 17135598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion with A1A1 genotype at DRD2 Taq1 locus
Number of subjects: 553
Study 17135598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion with TC genotype at C957T locus
Number of subjects: 553
Study 17135598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and polymorphisms
Number of subjects: 553
Study 14584489 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 4732
Study 14584489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4732
Study 11125656 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion-focused belief (reward used to encourage purchase)
Number of subjects: 2
Study 11125656 — intervention group
Group type: COMPARATOR
Intervention: Reward-focused belief (promotion used to distribute the reward)
Number of subjects: 2
Study 8836264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 300 mg (bolus followed by continuous infusion)
Number of subjects: 76
Study 8836264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 1417380 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (0.1 mg/24 h for 4 days, then 0.2 mg/24 h for 3 days, continued for 6 weeks after target quit day)
Number of subjects: 213
Study 1417380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 1417380 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 213
Study 6719387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (375 mg/d)
Number of subjects: 55
Study 6719387 — intervention group
Group type: EXPERIMENTAL
Intervention: RA 233 (1500 mg/d)
Number of subjects: 55
Study 6719387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 30185580 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational items in participant information leaflets (PILs)
Number of subjects: 20
Study 27085624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guérin (BCG)
Number of subjects: 229
Study 27085624 — intervention group
Group type: COMPARATOR
Intervention: Combination of Epirubicin (EPI) and Interferon-α2a (IFN)
Number of subjects: 229
Study 24550472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol elevation over 8 days
Number of subjects: 0
Study 24550472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24550472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol elevation
Number of subjects: 0
Study 21071561 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokefree Class Competition intervention
Number of subjects: 3490
Study 21071561 — intervention group
Group type: COMPARATOR
Intervention: Control group (not participating in the intervention)
Number of subjects: 3490
Study 20720535 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT) 24 IU or 40.32 μg
Number of subjects: 36
Study 20720535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18234715 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 17
Study 18234715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16158782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal budesonide plus oral zafirlukast twice a day
Number of subjects: 36
Study 16158782 — intervention group
Group type: COMPARATOR
Intervention: Nasal budesonide plus oral loratadine/pseudoephedrine twice a day
Number of subjects: 36
Study 16158782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 36
Study 14636795 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based smoking prevention intervention including a mailed parental smoking prevention kit, outreach follow-up telephone calls, child materials, medical record cues, and parent newsletter.
Number of subjects: 4026
Study 14636795 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 4026
Study 12043956 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg (Avandia tablets, 4 mg x 2)
Number of subjects: 9
Study 12043956 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg after pretreatment with sucralfate 2 g (Recolfate tablets, 1 g x 2)
Number of subjects: 9
Study 12043956 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 9
Study 10078678 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (500 mg orally)
Number of subjects: 22
Study 10078678 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 22
Study 7488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide 10 mg
Number of subjects: 402
Study 7488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide 25 mg
Number of subjects: 402
Study 7488280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 7488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (10 mg and 25 mg)
Number of subjects: 402
Study 7488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide and Placebo
Number of subjects: 402
Study 7488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 402
Study 2148849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridogrel (2 x 300 mg per day for 2 1/2 days)
Number of subjects: 0
Study 2148849 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 x 300 mg per day for 2 1/2 days)
Number of subjects: 0
Study 7016067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (various doses)
Number of subjects: 77
Study 7016067 — intervention group
Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 77
Study 7016067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (2,400 mg/day)
Number of subjects: 77
Study 30675096 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement (improved method with a negative pressure drainage)
Number of subjects: 117
Study 30675096 — intervention group
Group type: COMPARATOR
Intervention: Conventional (conventional anterior neck region negative pressure drainage)
Number of subjects: 117
Study 28608787 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day anal sexual exposure
Number of subjects: 485
Study 28608787 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of consistent condom use
Number of subjects: 485
Study 28608787 — intervention group
Group type: COMPARATOR
Intervention: Denial of receptive anal sex
Number of subjects: 485
Study 25855055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral consumption of Respecta(®) complex (L. acidophilus La‐14, L. rhamnosus HN001, and bovine lactoferrin) twice daily for 2 weeks
Number of subjects: 40
Study 25855055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral consumption of Respecta(®) complex
Number of subjects: 40
Study 24285581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 175
Study 24285581 — intervention group
Group type: COMPARATOR
Intervention: Control diet (low fat)
Number of subjects: 175
Study 24285581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra virgin olive oil
Number of subjects: 175
Study 22473713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir (300 mg BID, 600 mg BID, 600 mg QD, or 800 mg QD)
Number of subjects: 94
Study 22473713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 19323965 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 566
Study 19323965 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 566
Study 17329659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Vaccine Day and educational campaign
Number of subjects: 70
Study 17329659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine Day alone
Number of subjects: 70
Study 17329659 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational campaign alone
Number of subjects: 70
Study 17329659 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 15334330 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg, four times daily via gastric tube)
Number of subjects: 39
Study 15334330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 15334330 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 39
Study 11590379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg/d)
Number of subjects: 213
Study 11590379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 9924229 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.5 micrograms kg‐1
Number of subjects: 180
Study 9924229 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1.0 micrograms kg‐1
Number of subjects: 180
Study 9924229 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 2.0 micrograms kg‐1
Number of subjects: 180
Study 7801753 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented porous Harris‐Galante type I socket
Number of subjects: 60
Study 7801753 — intervention group
Group type: COMPARATOR
Intervention: Cemented all‐polyethylene Charnley socket
Number of subjects: 60
Study 3384588 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of pyridoxine-HCl daily supplementation for one year
Number of subjects: 0
Study 3384588 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 29761687 — intervention group
Group type: EXPERIMENTAL
Intervention: eSWL
Number of subjects: 74
Study 29761687 — intervention group
Group type: COMPARATOR
Intervention: dSWL
Number of subjects: 74
Study 27550387 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) as add-on therapy
Number of subjects: 104
Study 24404819 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home monitoring (n=55)
Number of subjects: 108
Study 24404819 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=53)
Number of subjects: 108
Study 21791459 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided exercises for 8 weeks
Number of subjects: 109
Study 20831130 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralization in conjunction with deproteinization prior to bleaching
Number of subjects: 40
Study 20831130 — intervention group
Group type: COMPARATOR
Intervention: Demineralization alone prior to bleaching
Number of subjects: 40
Study 18215562 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable navigation system (smartphone)
Number of subjects: 32
Study 18215562 — intervention group
Group type: COMPARATOR
Intervention: Paper map
Number of subjects: 32
Study 15993724 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Inspiratory Impedance Threshold Device (ITD)
Number of subjects: 22
Study 15993724 — intervention group
Group type: COMPARATOR
Intervention: Sham Inspiratory Impedance Threshold Device (ITD)
Number of subjects: 22
Study 14687872 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (150 mg/day)
Number of subjects: 400
Study 14687872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 10869584 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 34
Study 10869584 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 34
Study 9177952 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide 600 mg per day
Number of subjects: 578
Study 9177952 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide 300 mg per day
Number of subjects: 578